Acrux and TruPharma launched their generic Dapsone 5% Gel in the US, targeting acne vulgaris treatment.

The move aligns with Acrux's strategy to commercialise its product pipeline.

The launch follows strong market performance, with Dapsone 5% Gel products exceeding US$15 million ($23 million) in annual sales ending October 2023, as per IQVIA data.